AMD not affected by vitreomacular adhesion

Article

Vitreomacular adhesion (VMA) does not affect the development of exudative age-related macula degeneration.

Vitreomacular adhesion (VMA) does not affect the development of exudative age-related macula degeneration, according to the results of a 4-year longitudinal study in Retina.

The prospective, longitudinal investigation, led by Dr Sebastian Waldstein, Department of Ophthalmology, Medical University of Vienna, Austria, included 49 patients with AMD who underwent optical coherence tomography (OCT) and fluorescein angiography (FA) every three months for four years.

Time-domain and spectral-domain OCT were used to assess vitreomacula adhesion. OCT and FA were also used to determine development of choroidal neovascularization (CNV). CNV incidences were compared in all patients, through the presence or absence of VMA.

Of the patients studied, nine presented with VMA at baseline and 18 patients experienced exudative changes during the observation period. Development of CNV was present in 33% of patients with pre-existing VMA and 38% in patients without VMA.

In VMA patients the mean interval from baseline to disease progression was 20 ± 19 months and 22 ± 13 months in patients without VMA. Rate of CNV development and time to disease progression were not significantly different between the groups.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.